Twincretin ' Impressive ' : Topline Data from Phase 3 Trial in Diabetes Twincretin ' Impressive ' : Topline Data from Phase 3 Trial in Diabetes

Tirzepatide, the first dual GIP and GLP-1 receptor agonist in advanced testing, showed potent antihyperglycemic and weight loss effects in the first of several phase 3 studies in type 2 diabetes.Medscape Medical News
Source: Medscape FamilyMedicine Headlines - Category: Primary Care Tags: Diabetes & Endocrinology News Source Type: news